Chemotherapy has been dominating the field of cancer treatment for a long time, however, its limitations have revealed over time. Therefore, several antigen proteins and chimeric receptorT cells (CAR-T) involved in immunotherapy acute lymphoblastic leukemia (ALL) myeloid (AML) introduced. This paper provides details on mechanisms, implemented investigations, drawbacks ALL AML. Current studies s...

Over 90% of leukemic blasts in patients with acute lymphoblastic leukemia express the marker CD22. Inotuzumab ozogamicin (INO) is a CD22-directed humanized monoclonal antibody conjugated to the potent cytotoxin, calicheamicin, via an acid labile linker. INO has shown high rates of response in the treatment of relapsed and refractory (R/R) ALL in single-agent studies, with fewer adverse effects ...